WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ:ACUS) today announced today that Dr. Arian Pano, M.D., Acusphere’s Internal Medical Monitor, is scheduled to present a poster entitled “Evaluation of ECG-Related Safety of Perflubutane Polymer Microspheres (PPM) Injectable Suspension in Chronic Stable Angina Patients Undergoing Stress Echocardiography in RAMP -1 and -2 Trials,” at EuroECHO 2007 in Lisbon, Portugal. PPM for injectable suspension is the generic name for ImagifyTM (IND AI-700). Dr. Pano’s presentation concludes that chronic stable angina patients evaluated in Acusphere’s Phase 3 clinical trials did not experience a significant increase in the risk of arrhythmia and ischemic ECG changes with use of Imagify during Rest or Dipyridamole Stress ECHO. The poster will be presented at the Lisbon Congress Center, on Friday, December 7, 2007, beginning at 10:00 AM local time. Dr. Pano served as the internal medical monitor during the Phase 3 clinical trials for Imagify. The conclusions in this abstract result from a collaboration between investigators at Massachusetts General Hospital Heart Center and the Duke Medical Center EKG Core Laboratory.
